In:
Cancer, Wiley, Vol. 129, No. 15 ( 2023-08), p. 2308-2320
Abstract:
Entospletinib with decitabine combination therapy was well tolerated in patients with acute myeloid leukemia who had TP53 mutations with or without a complex karyotype or had a complex karyotype without TP53 mutations. Remission rates were low, and overall survival was short.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v129.15
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1